Immutep Limited (NASDAQ:IMMP – Get Free Report) was the target of a large decrease in short interest in July. As of July 31st, there was short interest totalling 4,730,000 shares, a decrease of 10.1% from the July 15th total of 5,260,000 shares. Based on an average trading volume of 372,100 shares, the days-to-cover ratio is currently 12.7 days.
Analyst Upgrades and Downgrades
A number of brokerages have recently issued reports on IMMP. Robert W. Baird decreased their target price on Immutep from $7.00 to $6.00 and set an “outperform” rating on the stock in a research report on Thursday, June 27th. Capital One Financial assumed coverage on Immutep in a report on Friday, May 17th. They issued an “overweight” rating and a $10.00 price objective on the stock.
Get Our Latest Research Report on Immutep
Immutep Trading Up 2.7 %
Hedge Funds Weigh In On Immutep
Institutional investors and hedge funds have recently bought and sold shares of the business. XY Capital Ltd purchased a new position in Immutep in the 2nd quarter worth approximately $105,000. PFG Investments LLC purchased a new position in Immutep during the first quarter worth approximately $119,000. Oracle Investment Management Inc. boosted its stake in Immutep by 9.4% during the first quarter. Oracle Investment Management Inc. now owns 564,879 shares of the biotechnology company’s stock worth $1,316,000 after buying an additional 48,449 shares during the last quarter. Virtu Financial LLC grew its holdings in Immutep by 269.4% in the 1st quarter. Virtu Financial LLC now owns 45,062 shares of the biotechnology company’s stock valued at $105,000 after buying an additional 32,864 shares in the last quarter. Finally, XTX Topco Ltd acquired a new stake in shares of Immutep in the 2nd quarter worth $26,000. 2.32% of the stock is currently owned by institutional investors and hedge funds.
About Immutep
Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.
Featured Articles
- Five stocks we like better than Immutep
- Ride Out The Recession With These Dividend Kings
- Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
- 3 Best Fintech Stocks for a Portfolio Boost
- 2 Option Strategies to Maximize Profits in a Bear Market
- What Investors Need to Know About Upcoming IPOs
- Lululemon Stock Gears Up for a Massive Comeback Rally
Receive News & Ratings for Immutep Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immutep and related companies with MarketBeat.com's FREE daily email newsletter.